Literature DB >> 7426315

Cyclophosphamide-induced lung damage in mice: protection by a small preliminary dose.

C H Collis, C M Wilson, J M Jones.   

Abstract

Cycylphosphamide (Cy) produces an interstitial pneumonitis in CBA mice. The extent of the lung damage has been quantified by measuring the increase in ventilation rate over 6 weeks after an i.p. injection of Cy 200, 250 and 300 mg/kg. A dose-dependent response was found. When a preliminary ("priming") dose of Cy at 50 mg/kg was given 7, 9 or 14 days before a single large dose of 250 mg/kg, lung damage was reduced, as shown by a smaller increase in ventilation rate than in those receiving 250 mg/kg alone, and this difference was significant (P less than 0.01) in the Day-14-and highly significant (P<0.001) in the Day-7-"primed" groups. When primed less than 7 days before, there was a relative increase in ventilation rate, which was statistically significant (P less than 0.01) in the Day-1-primed group. Similar effects were also seen in the survival of the mice.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7426315      PMCID: PMC2010345          DOI: 10.1038/bjc.1980.167

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide.

Authors:  T X O'Connell; M C Berenbaum
Journal:  Cancer Res       Date:  1974-07       Impact factor: 12.701

2.  The type 2 cell as progenitor of alveolar epithelial regeneration. A cytodynamic study in mice after exposure to oxygen.

Authors:  I Y Adamson; D H Bowden
Journal:  Lab Invest       Date:  1974-01       Impact factor: 5.662

3.  Accelerated regeneration of transplanted hematopoietic stem cells in irradiated mice pretreated with cyclophosphamide.

Authors:  S A Gregory; W Fried; W H Knospe; F E Trobaugh
Journal:  Blood       Date:  1971-02       Impact factor: 22.113

4.  [Diffuse interstitial fibrosis of the lung in Hodgkin's disease treated by high doses of endoxan].

Authors:  R André; H Rochant; B Dreyfus; G Duhamel; J C Péchère
Journal:  Bull Mem Soc Med Hop Paris       Date:  1967 Nov 3-10

Review 5.  Quantification of combined radiation therapy and chemotherapy effects on critical normal tissues.

Authors:  T L Phillips; K K Fu
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

6.  Sclerosing alveolitis induced by cyclophosphamide. Ultrastructural observations on alveolar injury and repair.

Authors:  V E Gould; J Miller
Journal:  Am J Pathol       Date:  1975-12       Impact factor: 4.307

7.  Sparing effect of cyclophosphamide (NSC-26271) pretreatment on animals lethally treated with gamma-irradiation.

Authors:  J L Millar; B N Hudspith
Journal:  Cancer Treat Rep       Date:  1976-04

8.  Cyclophosphamide therapy and interstitial pulmonary fibrosis.

Authors:  A R Patel; P C Shah; H L Rhee; H Sassoon; K P Rao
Journal:  Cancer       Date:  1976-10       Impact factor: 6.860

9.  Enhancement by drugs of metastatic lung nodule formation after intravenous tumour cell injection.

Authors:  L M van Putten; L K Kram; H H van Dierendonck; T Smink; M Füzy
Journal:  Int J Cancer       Date:  1975-04-15       Impact factor: 7.396

10.  Reduced lethality in mice receiving a combined dose of cyclophosphamide and busulphan.

Authors:  J L Millar; B N Hudspith; N M Blackett
Journal:  Br J Cancer       Date:  1975-08       Impact factor: 7.640

View more
  10 in total

1.  Cyclophosphamide-induced pulmonary toxicity.

Authors:  D W Siemann; L Macler; D P Penney
Journal:  Br J Cancer Suppl       Date:  1986

2.  Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome.

Authors:  Valentina Vavassori; Elisabetta Mercuri; Genni E Marcovecchio; Maria C Castiello; Giulia Schiroli; Luisa Albano; Carrie Margulies; Frank Buquicchio; Elena Fontana; Stefano Beretta; Ivan Merelli; Andrea Cappelleri; Paola Mv Rancoita; Vassilios Lougaris; Alessandro Plebani; Maria Kanariou; Arjan Lankester; Francesca Ferrua; Eugenio Scanziani; Cecilia Cotta-Ramusino; Anna Villa; Luigi Naldini; Pietro Genovese
Journal:  EMBO Mol Med       Date:  2021-01-21       Impact factor: 12.137

3.  Modulation of cyclophosphamide-induced early lung injury by curcumin, an anti-inflammatory antioxidant.

Authors:  N Venkatesan; G Chandrakasan
Journal:  Mol Cell Biochem       Date:  1995-01-12       Impact factor: 3.396

4.  Cyclophosphamide induced early biochemical changes in lung lavage fluid and alterations in lavage cell function.

Authors:  N Venkatesan; G Chandrakasan
Journal:  Lung       Date:  1994       Impact factor: 2.584

5.  Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane.

Authors:  S Rosenow; K L Kooistra; G Powis; R A Van Dyke
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Role of tumour necrosis factor and reactive oxygen intermediates in lipopolysaccharide-induced pulmonary oedema and lethality.

Authors:  S Gatti; R Faggioni; B Echtenacher; P Ghezzi
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

7.  Modulation of bleomycin-induced pulmonary fibrosis in the BALB/c mouse by cyclophosphamide-sensitive T cells.

Authors:  D J Schrier; S H Phan
Journal:  Am J Pathol       Date:  1984-08       Impact factor: 4.307

8.  Priming with low doses of methyl-CCNU reduce the toxicity of high doses of methyl-CCNU and melphalan, and increase the lifespan of mice implanted with Lewis lung carcinoma.

Authors:  A Zimber; K Perk; I Livnat
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

Review 9.  The role of toxicological interactions in lung injury.

Authors:  H P Witschi; P J Hakkinen
Journal:  Environ Health Perspect       Date:  1984-04       Impact factor: 9.031

10.  Prevention of acute deaths in mice after very high dose cyclophosphamide by divided dose schedule.

Authors:  B D Evans; I E Smith; R D Clutterbuck; J L Millar
Journal:  Br J Cancer       Date:  1984-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.